The rules that govern complementation of mutant and wild-type mitochondrial genomes in human cells were investigated under different experimental conditions. Among mitochondrial transformants derived from an individual affected by the MERRF (myoclonus epilepsy associated with ragged red fibers) encephalomyopathy and carrying in heteroplasmic form the mitochondrial tRNALYS mutation associated with that syndrome, normal protein synthesis and respiration was observed when the wild-type mitochondrial DNA exceeded 10% of the total complement. In these transformants, the protective effect of wild-type mitochondrial DNA was shown to involve interactions of the mutant and wild-type gene products. Very different results were obtained in experiments in which two mitochondrial DNAs carrying nonallelic disease-causing mutations were sequentially introduced within distinct organelles into the same human mitochondrial DNA-less (p°) cell. In transformants exhibiting different ratios of the two genomes, no evidence of cooperation between their products was observed, even 3 months after the introduction of the second mutation. These results pointed to the phenotypic independence of the two genomes. A similar conclusion was reached in experiments in which mitochondria carrying a chloramphenicol resistance-inducing mitochondrial DNA mutation were introduced into chloramphenicol-sensitive cells. A plausible interpretation of the different results obtained in the latter two sets of experiments, compared with the complementation behavior observed in the heteroplasmic MERRF transformants, is that in the latter, the mutant and wild-type genomes coexisted in the same organelles from the time of the mutation. This would imply that the way in which mitochondrial DNA is sorted among different organelles plays a fundamental role in determining the oxidative-phosphorylation phenotype in mammalian cells. These results have significant implications for mitochondrial genetics and for studies on the transmission and therapy of mitochondrial DNA-linked diseases.
Despite the large number of studies on the expression of artificially produced mitochondrial DNA (mtDNA) mutations and the phenotype of somatic cell hybrids and cybrids, information on mitochondrial genome interactions in mammalian cells is still very limited. The dependence of such interactions on the distribution of the mtDNA molecules among the mitochondria, which changes continuously throughout division and, possibly, fusion of the organelles, and the difficulty of investigating mtDNA sorting in a cell account in part for the present lack of understanding of how much the mitochondrial genomes interact in mammalian cells. The recent discovery of a variety of mtDNA mutations associated with diseases in humans (47) and the growing evidence of accumulation of mtDNA mutations with aging in somatic tissues (12-14, 19, 43) have raised a number of questions about the occurrence and frequency of intermixing of mutant and wild-type mtDNA and/or their products within a cell and the role that complementation or competition phenomena between these products play in determining the cell phenotype. While it is clear that the respiratory competence of a cell containing both mutant and wild-type mtDNA (heteroplasmic) depends on the proportion of the two types of mtDNA and on the capacity of their products to cooperate or compete with each other, only * Corresponding author. fragmentary data on the mechanisms which would permit such cooperation or competition to occur are available.
Evidence derived from the analysis of heteroplasmic cybrids produced by transfer of mitochondria from patients affected by the MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) encephalomyopathy, caused by a mitochondrial tRNALeU(UUR) mutation, into mtDNA-less (p°) cells (8) and from the investigation of myotubes that are heteroplasmic for the MERRF (myoclonus epilepsy associated with ragged red fibers) mitochondrial tRNALYS mutation (5) has clearly indicated that a small minority of wild-type mtDNA can protect the cell against the phenotypic effects of the mtDNA mutation. However, such experiments did not clarify whether this protective effect reflects the capacity of the wild-type mtDNA minority to provide enough respiratory capacity for the cellular needs even when completely segregated from the mutant mtDNA or, alternatively, whether intermixing and cooperation of the wild-type and mutant gene products, presumably through mitochondrial fusion, are required for the protective effect to occur.
Evidence suggesting cooperation between the products of wild-type and deleted mtDNA in cybrids derived from cells of a patient affected by chronic external ophthalmoplegia has been provided by the observation of translation products corresponding in size to the expected fusion proteins encoded in the deleted mtDNA (20) . In fact, because of the removal of essential tRNA genes by the deletion, the synthesis of such fusion products would require the participation of tRNAs transcribed from the wild-type genomes. Similarly, competition for tRNAs encoded in wild-type mtDNA by mRNAs transcribed from wild-type and mutant mtDNAs, again pointing to intermixing of mitochondrial gene products, has been suggested to occur in segments of skeletal muscle fibers of patients affected by a mitochondrial disease (Kearns-Sayre syndrome) characterized by accumulation of large-scale deletions in mtDNA (41) . However, in both of the above-mentioned cases, the results could not distinguish between the possibility that the presence of normal and deleted mtDNAs in the same mitochondrion resulted from fusion of two homoplasmic mitochondria, one containing only deleted mtDNA and the other containing only wild-type mtDNA, and the preexistence of both mtDNAs in the same mitochondrion from the time of the mutation event. Evidence which had been interpreted to suggest an intermixing and cooperation of gene products of mutant and wild-type mtDNAs originally carried in distinct organelles had been reported in an earlier study involving hybrids or cybrids between chloramphenicol (CAP)-sensitive (CAPS) human cells and CAP-resistant (CAPr) cells or cytoplasts derived therefrom, respectively (35) .
In this study, the availability of donor cells derived from patients affected by either of two mitochondrial diseases caused by mutations in distinct mitochondrial tRNA genes has allowed us to introduce independently the two mtDNAs into the same p0 cell and thus to test the occurrence of complementation between mitochondrial genomes carried by originally distinct organelles in the absence of a significant background due to lack of complementation. No evidence of cooperation was observed between the products of the two genomes, pointing to the phenotypic independence of these genomes. Similarly, no interactions between mutant and wildtype mtDNAs were detected in experiments in which mitochondria carrying CAP' mtDNA were introduced by cytoplast fusion into CAPS cells. In contrast to the above situations, in heteroplasmic MERRF transformants, derived from donor cells in which the mutant and wild-type genomes coexisted from the mutation event, extensive interactions between mutant and wild-type gene products were observed, pointing to a probable intramitochondrial event.
MATERIALS AND (31, 32) and shown to exhibit a T-to-C transition at position 2991, one of three known sites of CAPY mutations in the 16S rRNA gene of mammalian cells (26) , was grown in DMEM with 10% calf serum, 3 jig of 8-azaguanine per ml, and 40 jig of CAP per ml.
Myoblast culture and mitochondrion-mediated p0206 cell transformation. A mass myoblast culture was established from a muscle biopsy specimen from a patient with MERRF by a previously reported procedure (29) and used for p0206 cell transformation by cytoplast fusion, carried out as described previously (25) . In particular, enucleated myoblasts were fused to -5 x 105 to 1 x 106 p0206 cells, and transformants were isolated and maintained in DMEM supplemented with 10% dialyzed FBS and 100 jig of BrdU per ml. The population doubling time (DT) of the transformants was determined by using the formula DT = (t -tj)log 2/(log N -log NO), where N is the cell number and t is the time when the cells were counted.
Subcloning (8) . The transformants were isolated in DMEM supplemented with 10% dialyzed FBS and 100 jig of BrdU per ml. In this medium, only unfused MELAS transformants and cybrids between these transformants and pT72 cytoplasts were expected to survive; residual nonenucleated pT72 cells or hybrids between these and the MELAS transformants were expected to be killed by BrdU phosphorylated by the thymidine kinase encoded in the pT72 nucleus. To identify the cybrids, the clones were screened for the presence of the MERRF mutation by PCR amplification of an mtDNA fragment encompassing the mutation, using a mismatched primer and NaeI restriction digestion, as described below. Six clones exhibiting the MERRF mutation were identified after screening 116 clones.
Fusion of CAP23 cytoplasts with 143B cells. In these experiments, a small number of CAP23 cells (-2,000 cells) were enucleated by centrifugation in the presence of cytochalasin B and then fused with a large excess of 143B cells (-106 cells). In a first fusion experiment, 13 cybrids were isolated and maintained in DMEM with 10% dialyzed FBS in the presence of 100 jig of CAP and 100 jig of BrdU per ml until the time of analysis (57 to 58 days after fusion). In a second experiment, 4 cybrids were maintained in 100 jig of CAP per ml until the time of analysis (36 days after fusion), and 12 cybrids were transferred, 31 50 mM KCl, 1 mM MgCl2) containing 100 pug of proteinase K per ml and 0.5% Tween 20 (24) . Total DNA from biopsy specimens was extracted as described previously (37) . For the detection of the MERRF A-*G transition in the mitochondrial tRNALYS gene (40, 53) at position 8344 in the Cambridge human mtDNA sequence, an mtDNA segment which encompasses the mutation was amplified by PCR, using a mismatched primer which generated a new NaeI site over the mutated template, and then digested with NaeI (52). In particular, samples of total cell DNA from the original muscle biopsy specimen, the mass myoblast culture, the mitochondrial transformants, or 143B cells were processed in a thermal cycler (Eppendorf or Perkin-Elmer Cetus), using Taq polymerase (Promega) and oligonucleotides corresponding to the L-strand between positions 8191 and 8210 and to the H-strand between positions 8345 and 8364 (5'-TCACTGTAAAGAGGTGC CGG; underlined nucleotides differ from the Cambridge sequence and create an NaeI site when the MERRF mutation is present) as primers. The amplified fragments were digested with NaeI in the presence of the 654-bp EcoRI-SalI fragment of pBR322 DNA as an internal marker for completion of digestion and analyzed by electrophoresis through a 5% polyacrylamide-7 M urea gel for the detection and quantitation of the MERRF mutation. In some experiments, as specified below, the amplified fragments were digested with NaeI in the presence of the 1,075-bp XmnI-KpnI fragment of pBluescript KS+ DNA as an internal digestion marker; equal amounts of the various mixtures were then analyzed by electrophoresis through a 5% polyacrylamide gel.
In order to quantitate the proportion of mtDNA molecules carrying the MERRF mutation in a DNA sample by specific restriction enzyme digestion of the mtDNA PCR products, a mixed-template standard curve was constructed (40) . For this purpose, the PCR-amplified products of the mtDNAs from the previously isolated pTl transformant, containing in homoplasmic form the MERRF mutation, and pT5 transformant, containing in homoplasmic form the corresponding wild-type sequence (9) , were cloned in the BamHI and EcoRI sites of the pBluescript KS+ vector (Stratagene), and mixtures in different ratios of the whole plasmids pKS+.pTl-1 and pKS+.pT5-2, containing the mutant and the wild-type sequence, respectively, were subjected to PCR amplification and NaeI digestion in the presence of the EcoRI-SalI fragment of pBR322 DNA mentioned above as an internal marker for completion of digestion. The products were run on a 5% polyacrylamide-7 M urea gel, and the proportion of digested and undigested molecules was determined by using an LKB laser densitometer after ethidium bromide staining. Figure la compares the mixed-template standard curve (T) thus constructed for the MERRF mutation with the mixed-product standard curve (P) constructed by mixing, in different ratios, the PCR products independently amplified from pKS+.pTl-1 and pKS+.pT5-2 and then subjecting the mixtures to restriction enzyme digestion. As To correct the data for the formation of heteroduplexes of wild-type and mutant mtDNA which may be partially or totally resistant to AatII digestion during PCR amplification, a template standard curve was constructed. For this purpose, an mtDNA fragment from CAP23 cells harboring the CAP' mutation and the corresponding mtDNA fragment from the VA2B cell line, the parent of CAP23, were amplified by PCR, and then mixtures in different ratios of the two PCR products were digested with AatII in the presence of the internal digestion marker and analyzed as specified above. Figure lb compares the mixed-template standard curve (T) thus constructed for the CAPr mutation with the mixed-product standard curve (P) constructed by mixing, in different ratios, the PCR products independently amplified from CAP23 mtDNA and VA2B mtDNA and then subjecting the mixtures to AatII digestion. Here too, one observes a significant difference between the T and P curves, which presumably reflects the presence of heteroduplexes. (a) Genotype of the proband muscle (Mu) biopsy specimen, the myoblast (Myo) culture, five mitochondrial transformants, and 143B cells, analyzed by PCR amplification of total DNA with a mismatched primer and by running the PCR products on a 5% polyacrylamide-7 M urea gel, as described in Materials and Methods. Indicated are the sizes of the uncut PCR product in the muscle, myoblast, and transformant DNA samples (165 bp) and that of the larger fragment (147 bp) produced by NaeI cleavage of the mutation-containing PCR product. The size of the PCR product in the proband-derived DNA samples is 9 bp smaller than that obtained in the 143B DNA sample (174 bp) because of a nonanucleotide deletion frequently present in Asian populations (22) structed by PCR amplification with oligonucleotides corresponding to positions 1503 to 1522 and 1981 to 2000 in the 28S rRNA gene (16) , purified on an agarose gel, and 32P labeled by random priming. Radioactivity was quantitated by laser densitometry of the autoradiograms.
Mitochondrial protein synthesis and 02 consumption analysis. Cultures of individual transformants or 143B cells (-2 x 105 cells) were labeled with [35S]methionine (>800 Ci/mmol, 25 pCi/ml) for 2 h in the presence of 100 pg of emetine per ml, and the samples were then washed, trypsinized, lysed with 1% sodium dodecyl sulfate (SDS), and run on SDS-exponential polyacrylamide gradient gels, as described previously (9) . 02 consumption measurements were made as detailed earlier (25) .
RESULTS
Isolation of heteroplasmic mitochondrial transformants carrying the MERRF tRNALYS mutation. The proband from which the myoblast cultures were derived was from a 25-yearold Japanese male with characteristic symptoms of MERRF syndrome, including myoclonic epilepsy, ataxia, dementia, and mitochondrial myopathy with ragged red fibers. His mother exhibited similar but milder symptoms. Analysis of DNA from muscle biopsy specimens showed the presence of the mitochondrial tRNALYS mutation in both the patient and the mother (52) . A mass myoblast culture was established from a muscle specimen of the proband, and myoblast-derived cytoplasts were fused to a large excess of p0206 cells. Eleven presumptive mitochondrial transformants were isolated by growing the cell fusion mixtures in medium containing BrdU and lacking uridine (25) . As shown in Fig. 2a , the muscle specimen and the mass myoblast culture exhibited the tRNALYS mutation in --91% of the mtDNA molecules. Nine of the 11 transformants were found to contain more than 90% mutant mtDNA, while the other 2 (KT5 and KT7) contained between 80 and 90% mutant mtDNA. These two transformants and three of the others (KT1, KT10, and KT11) were chosen for further study and maintained in continuous culture over an 8-to 9-month period. During this time, in KT1, KT10, and KT11, the wild-type mtDNA level remained constant at 5 to 8%, whereas in KT5 and KT7, the wild-type mtDNA level declined fairly rapidly from 15 and 17%, respectively, 1 to 2 months after isolation, to -9%, and slowly reached a level of 6 to 7% after 7 months. Figure 2b displays the mitochondrial translation products of the transformants labeled with [35S]methionine for 2 h in the presence of 100 ,ug of emetine per ml 16 to fusion. Considerable variability in the labeling of the mtDNAencoded proteins was observed among the transformants. Transformants KT1, KT10, and KT11 showed various decreases in protein labeling relative to the 143B parental cells, as well as the presence of an abnormal translation product migrating faster than ND4 (asterisks in Fig. 2b ) previously identified as characteristic of MERRF patient myoblasts (5, 9) and p0 transformants derived therefrom (9). By contrast, the level of labeling and the pattern of the mitochondrial translation products of KT5 and KT7, which at the time of analysis had a mutant mtDNA content of 91 and 87%, respectively, appeared to be fairly similar to those of 143B cells, with a small amount of the abnormal band. Correspondingly, the rate of 02 consumption, analyzed 15 to 17 weeks after fusion, was strongly decreased in KTi, KT10, and KT11 (<0.7 fmol/min/ cell), moderately decreased in KT5 (2.5 fmol/min/cell), and only slightly reduced in KT7 (3.8 fmol/min/cell) compared with the rate in 143B cells (Fig. 2c) .
Subcloning of MERRF transformants. In order to investigate the intercellular heterogeneity in genotype and phenotype of the transformants, five to seven subclones were isolated, as described in Materials and Methods, from each of the KT1, KT5, and KT7 clones, at times corresponding, respectively, to 8, 8 and 14, and 14 weeks after their isolation. As shown in Fig.  3 , the individual subclones from each transformant exhibited relatively little variation in the proportion of wild-type mtDNA, with its average approaching that of the parental clone (10 versus 7% in KT1, 9 versus 12% and 11 versus 9% in KT5, and 14 versus 14% in KT7). The KT1 subclones all showed clearly reduced labeling of the mitochondrial translation products, with a relatively pronounced abnormal band (asterisks) (barely visible for clone 4 because of the extreme decrease in protein synthesis), and strongly decreased 02 consumption (Fig. 3) . The KT5 subclones showed heterogeneity in the phenotypic expression of the mutation; two, subclones 5 and 6, exhibited a variable reduction in labeling of the mtDNA-encoded polypeptides, with a relatively large amount of the abnormal band and a strong reduction in 02 consumption, while the others showed a normal or near-normal level of labeling, with a small or negligible amount of abnormal band and a substantial to strong decrease in 02 consumption. The K7 subclones, except for subclone 1, which exhibited a small amount of the characteristic abnormal band recognizable for its diffuse appearance (asterisk), showed a normal mitochondrial translation pattern, although with somewhat decreased labeling of the protein products; furthermore, they exhibited a variable reduction in 02 consumption (Fig. 3) .
Complementation of defects caused by the MERRF mutation by a small minority of wild-type mtDNA. The data discussed in the two previous sections indicated that wild-type mtDNA, even when present in relatively small amounts, can exert a protective effect against manifestation of the MERRF mutation-associated respiration defect. Figure 4a summarizes the relationship between the proportion of wild-type mtDNA and respiratory capacity in different MERRF transformants isolated in the present work and tested at various times after their isolation. The diagram clearly illustrates the existence of a sharp transition, with a mid-point at a wild-type mtDNA proportion of -8%, in the ability of wild-type mtDNA to protect against manifestation of the respiration defect, with full protection by -10% wild-type mtDNA (Fig. 4a) . During prolonged growth of the KT7 transformant, while the percentage of wild-type mtDNA decreased from -17 to -7.5%, passing through the transition in its protective capacity men- tioned above, no significant change was observed in the mtDNA content per cell (data not shown). This indicates that the threshold in wild-type mtDNA proportion above which this DNA protects against the phenotypic effects of the mutation reflects an equivalent sharp threshold in the absolute amount of wild-type mtDNA. The data for the KT1, KT5, and KT7 subclones also show a similar protective effect of wild-type mtDNA against the phenotypic expression of the MERRF mutation, but the mid-point transition is displaced towards a 12% proportion of wild-type mtDNA for unknown reasons (Fig. 4b) .
In order to investigate whether the protective effect of wild-type mtDNA involved an interaction of the wild-type and mutant gene products, advantage was taken of the fact that the abnormal band migrating slightly faster than ND4 which was mentioned above (Fig. 2b and Fig. 3 ) provided a molecular marker of the protein synthesis defect associated with the MERRF mutation. Figure 4c shows the relationship between the proportion of wild-type mtDNA and the amount of radioactivity in the abnormal band, expressed relative to the total amount of label in the ND5, COI, and ND4 translation products, in different KT1, KT5, and KT7 subclones. Again, there appears to be a sharp transition, with a mid-point at a wild-type mtDNA proportion of -9%, above which the abnormal band decreases sharply in amount. This result indicates that the threshold in the protective effect of wild-type mtDNA involves primarily the restoration of normal mitochondrial protein synthesis and, as a consequence, the re-establishment of respiratory competence. Furthermore, and more importantly, the disappearance of the abnormal band strongly suggests that the protective effect depends in part on the intermixing and cooperation of the wild-type and mutant gene products.
Absence tion or from a genotype shift of this double-genome transformant towards the MERRF genotype is not known. Figure 5c shows the percentages of MERRF mtDNA, MELAS mtDNA, and wild-type mtDNA observed in the above transformants and in the parent cell lines. The MERRF mtDNA content varied among the five double-genome transformant clones between -64 and -87%, the MELAS mtDNA content varied between -12 and -35%, and the wild-type mtDNA content varied between 0 and -2%. Figure Sd It was shown above that 10% or more of wild-type genes have a fully protective effect against the manifestation of the biochemical defects caused by the MERRF tRNALYS mutation, as reported for the MELAS tRNALeu(UUR) mutation (8) . In the present experiments, the MERRF mutation-containing mtDNA was expected to act like wild-type mtDNA in protecting the cell against the MELAS mutation if intergenome complementation occurred. Similarly, the MELAS mutationcontaining mtDNA was expected to act like wild-type mtDNA in protecting against the MERRF mutation. The sum of wild-type mtDNA and MERRF mutation-containing mtDNA varied between 65 and 72% and the sum of wild-type mtDNA and MELAS mutation-containing mtDNA varied between 29 and 36% in every double-genome transformant clone except 2SD x pT72-24. However, in this clone, the sum of wild-type mtDNA and MELAS mutation-containing mtDNA was 14%, i.e., above the threshold for protection against the phenotypic effect of the MERRF mutation. Therefore, it was expected that if there was genome interaction, there would be reciprocal complementation between mtDNA containing the MERRF or the MELAS mutation and mtDNA lacking that mutation in all five double-genome transformants. On the contrary, it is clear from Fig. 6 that the labeling of the mitochondrial translation products in the double-genome transformants (measured 42 to 99 days after fusion) during a 2-h [35S]methionine pulse was lower than the labeling in the parental cell lines. Particularly striking is the marginal labeling of the mitochondrial translation products in the transformants 59A x pT72-22, 59A x pT72-34, 2SD x pT72-25, and 2SD x pT72-45 (Fig. 6b) . Densitometric quantitation of the labeling of the mtDNA-encoded polypeptides in the four double-genome transformants mentioned above showed a level of about 1% of the value observed in 143B cells (Fig. 7a) . In agreement with the protein labeling data, there was no recovery of respiration capacity in any of the double-genome transformants, their rates of 02 consumption (measured within a few days from the protein synthesis analysis) varying between 6.8 and 14% of that in 143B cells (Fig.  7b) . In particular, in the four transformants with a negligible level of mitochondrial protein synthesis, the rate of 02 con- sumption (0.34 to 0.48 fmol/min/cell) approached the level found in p°206 cells (25) . An interesting observation is the relatively high level of labeling of the mitochondrial translation products (a60% of the level in 143B) and rateOf o2consump-tion (p30% of the level in 143B) in the parental line 2SD, which had the highest mtDNA content (o3. indicated by the experiments discussed in the previous section, was at variance with previously reported findings (35) . These findings had been interpreted to suggest that HT1080 mtDNA, carrying a 16S rRNA gene mutation that conferred CAP resistance of mitochondrial protein synthesis on the cells, allowed the synthesis of a HeLa cell mtDNA-encoded variant ND3 polypeptide (originally named MV2 and subsequently renamed ND3' on the basis of the functional identification of the ND3 gene [9] ) in the presence of CAP after introduction by cybrid or hybrid fusion into HeLa cells. This interpretation implied an interaction of CAP' ribosomes from HT1080 cell mitochondria with mRNA from HeLa cell mitochondria. The presence of the variant ND3' polypeptide in HeLa cells has been correlated with a mutation in the ND3 gene that converts an asparagine codon to an aspartic acid codon, and its faster electrophoretic mobility compared with that of the normal ND3 polypeptide has been interpreted to result from either proteolytic digestion, the loss of a potential glycosylation site, or the addition of a charge group (34) . In order to verify the occurrence of interactions between the products of CAPY and CAPS mtDNAs carried in originally distinct organelles in the same 143B nuclear background of the double-genome transformants investigated here, cybrids were constructed between cytoplasts from CAP23, a derivative of the human cell line VA2B, which carries an mtDNA mutation in the 16S rRNA gene conferring CAP resistance (26, 31) , and the CAPS 143B cell line. A favorable situation in these experiments was the fact that CAP23 exhibits the same ND3 polymorphism described for HeLa (Fig. 8a) . By contrast, the 16 cybrids isolated in the second experiment, which had been kept in medium containing 100 ,ug of CAP per ml for 36 days or maintained in this medium for 31 days and then transferred to a medium containing 25 jig of CAP or 25 ,ug of CAP plus 50 jig of uridine per ml for 5 days, exhibited lower proportions of CAPr mtDNA, from 9 to 53% (average, 27%). Figure 8b shows the genotype analysis of the parental cell lines 143B, VA2B, and CAP23 and of eight cybrids with various proportions (between 10 and 89%) of CAP' mtDNA, chosen from those isolated in the first and second fusion experiments. Figure 8c shows the pattern of mitochondrial protein synthesis after a 2-h exposure of the cells to [35S]methionine in the absence and presence of 100 jig of CAP per ml in the parental lines and in six of the eight cybrid clones. The mitochondrial translation patterns observed in the absence of CAP in 143B cells on one side and in VA2B and CAP23 cells on the other were identical except for the exclusive presence of the ND3 normal gene product in 143B cells and for a greatly reduced amount of the ND3 polypeptide and a predominant amount of the variant ND3' product in VA2B and CAP23 cells. The coexistence of a small amount of the ND3' variant polypeptide with a prevalent normal ND3 product had been reported previously for HeLa cells (35) . Also to be noticed is the fact that the labeling of the mitochondrial translation products in CAP23 cells was significantly reduced compared with that in either 143B cells (by 25%) or VA2B cells (by 39%), in agreement with earlier observations (50 (Fig. 8d, solid circles and solid line) , in agreement with the assumption of genetic independence of the CAP23-derived and 143B-derived mitochondria. If no correction is applied to the protein synthesis data, the line best fitting the data (dashed line in Fig. 8d ) becomes more pronouncedly curved, as would be expected if there were at least partial interactions between the CAPr and CAPS genomes, with the latter being dominant. However, a dominance of the CAPS allele would be in contrast to the available evidence from bacterial systems indicating that the CAPS ribosomes are not "frozen" by CAP on the polysomes and are therefore not expected to block the passage of the resistant ones (18) ; also, the well-documented isolation of CAPr mutants of Saccharomyces cerevisiae (4, 7) and mammalian cells (44, 48) under selective conditions, which would require the initial expression of single mutant mtDNA molecules mixed with wild-type molecules, argues strongly against a dominance of the CAPS allele. Therefore, the data are most consistent with the conclusion that the CAPr and CAPS genomes in these cybrids are phenotypically independent.
Additional evidence in favor of the above conclusion was provided by analysis of the expression, in the absence and presence of CAP, of the normal ND3 gene product and ND3' variant product in the cybrids (Fig. 8c) . In fact, the two cybrids with strongly predominant CAPr mtDNA (5 and 16) exhibited a prominent ND3' band and a weak ND3 band in both the absence and the presence of CAP. It seems very likely that this weak ND3 band derives from the mitochondria containing wild-type mtDNA in heteroplasmic form transferred with the CAP23 cytoplasts. Conversely, the two cybrids with minor proportions of CAPr mtDNA (36 and 43) exhibited a prominent ND3 band in the absence of CAP and only a trace of this band in the presence of CAP; a very weak ND3' band was visible in these two cybrids in both the absence and the presence of the drug. In the two cybrids with intermediate proportions of CAPr mtDNA (35 and 39) , the protein labeling pattern in the absence of CAP showed a fairly strong ND3 band which was markedly reduced (-88%) in the presence of CAP and a weaker ND3' band which was only slightly affected (-20%) by exposure of the cells to the drug. This result was consistent with the phenotypic independence of the CAP' and CAPS genomes in the cybrids. The fact that the labeling of the ND3' band in the latter experiments (ND3'/[ND3 + ND3'] _ 15%) was lower than expected from the proportion of CAPr mtDNA (59 to 61%) is presumably due at least in part to the lower protein-synthetic capacity of the CAP23 mitochondria.
DISCUSSION
The present article has addressed fundamental questions of mammalian mitochondrial genetics, namely, whether mutant and wild-type mtDNA molecules can interact with each other within a cell and whether the distribution of the two types of mtDNA molecules among mitochondria can influence this capacity. Two different situations were investigated, one in-VOL. 14, 1994 143 B The CAP' mutation was analyzed in the parental cell lines 143B and CAP23 and in 13 cybrids isolated in the first fusion experiment (time of analysis, 57 days after fusion) by PCR amplification of total cell DNA with a mismatched primer and by running the PCR products on a 5% polyacrylamide gel, as described in Materials and Methods. Indicated are the size of the uncut PCR product (198 bp) and that of the larger fragment produced by AatII cleavage of the mutation-containing PCR product (173 bp). (b) The CAPr mutation was analyzed in 143B cells, CAP23 cells, VA2B cells, and eight cybrids: of these, two (5 and 16) were isolated in the first fusion experiment (time of analysis, 58 and 59 days after fusion, respectively) and six were isolated in the second fusion experiment, maintained for 31 days in medium containing 100 ,ug of CAP per ml, and then kept for 12 to 17 days in medium containing 25 ,ug of CAP per ml (35, 36, and 39) volving the simultaneous introduction into a p°206 cell of mitochondria containing mtDNA with a deleterious mutation and the corresponding wild-type mtDNA from the same donor cell, and the other involving the introduction of mitochondria carrying a mutant or wild-type gene into cells already containing the corresponding wild-type or mutant allele. In both situations, transformants exhibiting various ratios of the two types of mtDNA were analyzed.
The first situation was investigated by introducing into p0206 cells mitochondria from cells of a patient carrying in heteroplasmic form the mitochondrial tRNALYS mutation associated with the MERRF encephalomyopathy. In these experiments, the occurrence of interactions between the products of mutant and wild-type mtDNAs was strongly suggested by the disappearance of the abnormal protein band migrating slightly faster than ND4 (5, 9), which is produced as a result of the mutation. Previous observations (9) on p0 cell transformants carrying the MERRF A-->G transition in the tRNALYS gene had indicated a direct relationship between the lysine residue content of the various mitochondrial translation products and the severity of inhibition of their synthesis, pointing to an alteration of tRNA function as being responsible for the strong depression of mitochondrial protein synthesis caused by the mutation. Although the origin of the abnormal band migrating faster than ND4 has not been identified yet, it is very likely that it represents a premature termination product of the translation of the mRNA for one of the three largest mitochondrial genes, i.e., ND5, COI, and ND4. Recent evidence (14a) has indicated that there is a strong decrease (60 to 70%) in the charging capacity for lysine of the mutated tRNALYS. In the present work, the almost complete disappearance of the abnormal band in the heteroplasmic transformants containing more than 10% wild-type mtDNA has clearly shown that there was extensive intermixing of wild-type and mutant gene products in these transformants and that the MERRF mutation behaved as a recessive, a finding which is consistent with a tRNALYS dysfunction caused by the mutation. Furthermore, these results have strongly suggested that the protective effect by a small minority of wild-type mtDNA depends, in part at least, on the interaction between the mutant and wild-type gene products.
A strikingly different conclusion from that discussed above concerning mitochondrial genome interactions has emerged from experiments involving the introduction of mitochondria containing a mutant or wild-type gene into cells already carrying the corresponding wild-type or mutant allele. Two such types of experiments were carried out. The first type of experiments took advantage of the availability of two mtDNAs carrying nonallelic disease-causing mutations, each causing a recognizable defective phenotype in the cells carrying it; this allowed a test of the occurrence of complementation between mitochondrial genomes carried by originally distinct organelles, with no significant background being associated with absence of complementation. These experiments involved the introduction into p0 cell transformants nearly homoplasmic for the MELAS mutation of mitochondria carrying about 100% mtDNA with the MERRF mutation. In these experiments, no evidence of cooperation between the products of the two mtDNAs was observed even 3 months after introduction of the second mutation, as judged from the absence of recovery of respiratory competence and of a normal rate of mitochondrial protein synthesis.
The recessive nature of the MERRF mutation and the observation that as little as 10% wild-type genes is able to fully complement the biochemical defects caused by the mutation would tend to exclude the possibility that this lack of cooperation between the MERRF and the MELAS genomes reflected an interference by the excess of mutant tRNALYS expected in the double-genome transformants analyzed here with the function of the wild-type tRNALYS. One can likewise exclude the possibility that the majority of the MERRF mutation-carrying genome is "incompatible" with the p0206 nuclear background of the recipient MELAS transformants. In fact, it has been shown previously that the mitochondrial genome of the same haplotype as that investigated here but lacking the MERRF mutation can confer full respiratory competence and a normal level and pattern of mitochondrial protein synthesis on p0206 cells (9) . In the case of the MELAS mutation, the previously reported full protection from the phenotypic effects of the mutation exerted by 10% wild-type mtDNA (8) also suggests that the mutation is recessive, arguing against significant interference by the mutated tRNAL-UeuUR) with the wild-type tRNALu(UUR). Even if the MELAS mutation were dominant, it seems extremely unlikely that a minority of MELAS mutation-carrying genomes would have a more drastic effect on mitochondrial protein synthesis and respiration than was previously observed in p0 cell transformants carrying nearly 100% of the same MELAS mutant genomes (8) .
The possibility that two unlinked recessive mutations occurring in the same cells may give a dominant phenotype, as has been described for some nuclear systems, also has to be considered. If this is the situation here, it may have produced a result similar to what would be expected from lack of complementation. However, the clear cases of such a phenomenon described previously are those in which the two mutations occur in proteins that interact with each other, like the subunits of an oligomeric complex. In another case, recently reported, concerning the effect of haywire gene mutations in testis-specific tubulin mutants of Drosophila melanogaster (33, 38) , one mutation alters a protein (haywire) that affects the expression of another gene product (,B-tubulin) required at high levels, and the other mutation alters the latter gene product. It seems very unlikely that the structural or functional gene product interactions occurring in the two situations mentioned above would apply to the case of two distinct tRNA gene mutations, considering the protective effect of only 10% wild-type genes against the phenotypic manifestation of either mutation.
On the basis of the evidence discussed above, the most plausible interpretation of the phenotype of the double-genome transformants of p0206 cells is that the products of the VOL. 14, 1994 MERRF mutation-and the MELAS mutation-carrying mtDNAs, originally carried in distinct organelles, did not interact with each other to any appreciable extent in the cybrids investigated here. This lack of genome interaction did not reflect the particular behavior of the MELAS and MERRF mutations but rather a more general phenomenon. In fact, similar results were obtained in a second type of experiment involving the introduction of mitochondria from CAP23 cells, carrying a nearly homoplasmic CAPr mutation in their mtDNA, into CAPS 143B cells. In these experiments also, no evidence of genome interaction was observed in the cybrids between the CAPr and CAPS mtDNAs, as judged from the reasonably good proportionality between percentage of residual mitochondrial protein synthesis in the presence of CAP and percentage of CAP' genomes and from the lack of synthesis, in the presence of the drug, of the 143B mtDNAencoded normal ND3 polypeptide.
The reason for the different conclusion reached by others in similar earlier experiments with cybrids or hybrids between CAPr HT1080 and CAPS HeLa cells (35) is not clear. Although one cannot exclude a role for the different nuclear background in the cybrids analyzed in the present and in the previous work (143B in the present CAPr_CAPS cybrids and HT1080 in the earlier-investigated CAPr_CAPS cybrids), it should be remarked that, in the above-cited work, the high sensitivity to CAP (70 to 90%) of both the gene products linked to the CAPS mtDNA and of those linked to CAPr mtDNA, including the putative ND3 and ND3' bands, makes those results difficult to interpret. In the present work, additional evidence against any significant cooperation between CAPS and CAPr mtDNA was provided by the nearly complete replacement of the resident CAPS mtDNA by the exogenous CAPr mtDNA observed in the cybrids 8 weeks after fusion. In fact, if there was such a cooperation, one would expect significant proportions of CAPS mtDNA to persist in the cybrids because of the lack of selective pressure against the CAPS mtDNA. These results confirm those obtained in earlier experiments, in which single organelles from CAP23 cells were injected into cells from two genetically independent human CAPS cell lines. In fact, in these experiments, a rapid complete replacement of the resident CAPS mtDNA by the CAPr mtDNA was demonstrated (26) .
The fundamental conclusion of the experiments discussed in this article is that interactions of mitochondrial genomes originally carried in distinct organelles occur rarely, if at all, in the cell lines analyzed here. Although the present work has not addressed directly the question of whether fusion occurred between organelles carrying different mtDNAs, the most plausible hypothesis is that the lack of interaction between the two genomes reflected their physical segregation in separate organelles, i.e., absence of mitochondrial fusion. There is other evidence in the literature that supports the idea that two types of mtDNA originally located in separate organelles tend to remain segregated in mammalian cells, including the gradual elimination of HeLa cell mtDNA in hybrids of HeLa cells and fibroblasts (21, 49) and the complete switch, in only one or a few generations, of mtDNA genotypes in Holstein cows (2, 28, 36) . A model assuming that the unit of segregation of mammalian mtDNA is the organelle itself and that the rapidity of segregation of mitochondrial alleles within heteroplasmic oocytes is therefore influenced by whether the individual organelles themselves are homoplasmic or heteroplasmic (23) likewise argues in favor of the genetic independence of the individual mitochondria within a mammalian cell.
The cell mosaicism observed in the distribution of mutant mtDNA in several mtDNA-encoded diseases (5, 9, 30, 41)
supports the same concept. The observation of heterogeneity in membrane potential among mitochondria in the same cell is also consistent with autonomy of the organelles (42) . In conjugated paramecia also, no complementation has been observed between genetically different types of mitochondria (1) . On the other hand, the evidence of mtDNA complementation and recombination clearly indicates that mitochondrial fusion does occur in other organisms, such as S. cerevisiae (10) , Chlamydomonas spp. (6) , and plants (39, 46) . However, it has also been found in yeast cells that, in p+ x p+ crosses, mtDNA mixing is not extensive and appears to be limited to that portion of the zygote which gives rise to medial buds and, furthermore, that the sorting of mtDNA is controlled differently from that of the bulk matrix protein constituents (3). In mammalian cells, the apparent lack of recombination between mtDNA molecules (11) certainly reduces the need for mitochondrial fusion. However, in mammalian systems, the evidence for the existence of an interconnecting mitochondrial network in some cell types in vivo also suggests the possibility that mitochondrial fusion may occur in certain situations under physiological or developmental control. The observation of restoration of normal mitochondrial protein synthesis in p0 cell transformants derived from heteroplasmic cells from an MERRF patient and containing more than 10% wild-type mtDNA and the previously reported findings of fusion proteins (20) and of competition for tRNAs (41) in cybrids and skeletal muscle segments carrying large mtDNA deletions have to be interpreted in the light of the evidence obtained in the present work on the lack of interactions between the products of two mtDNAs carried by originally distinct organelles. In fact, it seems likely that, in all the above-mentioned cases, in which there was obviously interaction of the mutant and wild-type genomes, these coexisted in the same organelles from the time of the mutation. Since each mitochondrion in most mammalian cells contains several mtDNA molecules, every mutant mtDNA molecule will in the beginning coexist in the same organelle with wild-type molecules. It is very reasonable to think that cells in which this intramitochondrial heteroplasmy is maintained will have a selective advantage because of the possibility of complementation that this situation allows. Therefore, the different results obtained in the two situations analyzed in the present work, namely, the occurrence of interactions of mutant and wild-type mitochondrial DNAs 
